| Pharmaceuticals | Branded generics, complex generics, specialty injectables, inhalers, biosimilars, ophthalmics | Strong R&D capabilities, global regulatory approvals, diverse product portfolio, and global marketing presence | B2B and B2C including hospitals, pharmacies, and healthcare institutions worldwide | Specialty injectables, biosimilars, and inhalation products | 22602 | 99 | Sales of formulations through retail, hospitals, and partnerships globally | Direct sales, contracts, licensing, and partnerships | Innovation in specialty products, complex generics, expanding US footprint, and digital health integration | Linvas, Gibtulio, Xopenex, Brovana, Namuscla, Rymti, Cialis |
| Others | Diagnostics and other health services | Growing consumer brand and integrated health ecosystem | Consumers and healthcare providers in India | Diagnostics services | 105 | 1 | Service revenues from diagnostics and healthcare programs | Service fees and healthcare product revenue | Expanding diagnostics business and consumer healthcare initiatives | |
